A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

NCT05631704 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: VH4524184
DRUG: Midazolam
DRUG: Placebo

Sponsor

ViiV Healthcare